I'rom Group Co EBIT per Share
Delisted
The EBIT per Share of I'rom Group Co (2372.T) as of Oct 14, 2026 is 93.66 JPY. In the previous year, EBIT per Share was 300.66 JPY — a change of -68.85% (lower).
Get this data via API
Financial Data API
EBIT per Share
93.66JPY
YoY
-68.85%
Last updated:
EBIT per Share of I'rom Group Co is 2024 93.66 JPY. EBIT per Share of I'rom Group Co was 2023 300.66 JPY. It decreases by -68.85% lower compared to the previous year.
The I'rom Group Co EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2019
101.16 JPY
Jan 1, 2020
101.81 JPY
Jan 1, 2021
88.62 JPY
Jan 1, 2022
228.51 JPY
Jan 1, 2023
300.66 JPY
Jan 1, 2024
93.66 JPY
Jan 1, 2025 (e)
0.00 JPY
Jan 1, 2026 (e)
0.00 JPY
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.00JPY | — |
| est | 0.00JPY | -100.00% |
| 93.66JPY | -68.85% | |
| 300.66JPY | +31.57% | |
| 228.51JPY | +157.85% | |
| 88.62JPY | -12.96% | |
| 101.81JPY | +0.65% | |
| 101.16JPY | +14.25% | |
| 88.54JPY | +355.72% | |
| 19.43JPY | -142.95% | |
| -45.23JPY | -39.91% | |
| -75.27JPY | +87.24% | |
| -40.20JPY | -198.05% | |
| 41.00JPY | -185.22% | |
| -48.11JPY | -226.24% | |
| 38.11JPY | -315.72% | |
| -17.67JPY | -378.95% | |
| 6.33JPY | -122.71% | |
| -27.89JPY | -80.47% | |
| -142.78JPY | -783.15% | |
| 20.90JPY | -62.75% | |
| 56.11JPY | — |
Access this data via the Eulerpool API
I'rom Group Co Stock analysis
What does I'rom Group Co do? I'rom Group Co. Ltd is a Japanese company specialized in medical services. It was founded in April 2007 and is headquartered in Tokyo, Japan. The company has become a significant player in the medical service sector in Japan within a few years. Its business model focuses on medical services and the sale of medical products, specifically in the areas of Life-Science and Clinical Research. I'rom offers support in clinical studies, distributes medications and medical devices, and provides CRM services. The company is divided into different divisions that offer various specialized products and services such as clinical research services, medical development services, corporate staffing services, and CRM services. I'rom also offers a wide range of medical products, mainly targeting the Japanese market. In conclusion, I'rom Group Co. Ltd is a leading company in the field of medical services in Japan, providing integrated support in product development and marketing for the life science and healthcare industries. I'rom Group Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about I'rom Group Co stock
EBIT per Share of I'rom Group Co is 93.66 JPY in 2024.
EBIT per Share of I'rom Group Co changed from 300.66 JPY to 93.66 JPY, representing a -68.85% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share I'rom Group Co since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — I'rom Group Co
All Key Metrics — I'rom Group Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth